T lymphoblastic leukemia/lymphoma
diseaseOn this page
Also known as precursor T lymphoblastic leukemia/lymphomaprecursor T lymphoblastic lymphoma/leukemiaprecursor T-lymphoblastic lymphoma/leukemia
Summary
T lymphoblastic leukemia/lymphoma (MONDO:0003537) is a cancer (an umbrella term covering 5 Mondo subtypes) and 13 clinical trials. Top therapeutic interventions include mercaptopurine anhydrous, asparaginase, and calaspargase pegol. A subtype of precursor lymphoblastic lymphoma/leukemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 5 Mondo subtypes
- Clinical trials: 13
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | T lymphoblastic leukemia/lymphoma |
| Mondo ID | MONDO:0003537 |
| DOID | DOID:5599 |
| NCIT | C8694 |
| UMLS | C1301359 |
| MedGen | 224897 |
| GARD | 0023552 |
| Is cancer (heuristic) | yes |
Also known as: precursor T lymphoblastic leukemia/lymphoma · precursor T lymphoblastic lymphoma/leukemia · precursor T-lymphoblastic lymphoma/leukemia
Disease family
An umbrella term covering 5 Mondo subtypes.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › precursor lymphoblastic lymphoma/leukemia › T lymphoblastic leukemia/lymphoma
Related subtypes (3): lymphoblastic lymphoma, acute lymphoblastic leukemia, B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormality
Subtypes (5): childhood precursor T-lymphoblastic lymphoma/leukemia, refractory precursor T-lymphoblastic lymphoma/leukemia, T-cell prolymphocytic leukemia, aggressive NK-cell leukemia, T-lymphoblastic lymphoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 13.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 4 |
| PHASE1 | 4 |
| PHASE1/PHASE2 | 2 |
| Not specified | 2 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07072585 | PHASE2/PHASE3 | NOT_YET_RECRUITING | Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) |
| NCT06712121 | PHASE2 | RECRUITING | Venetoclax and Decitabine in R/R T-ALL |
| NCT07153068 | PHASE1/PHASE2 | RECRUITING | SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies |
| NCT07244380 | PHASE2 | NOT_YET_RECRUITING | Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL. |
| NCT02538926 | PHASE2 | WITHDRAWN | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma |
| NCT04762485 | PHASE1/PHASE2 | UNKNOWN | Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia |
| NCT05991973 | PHASE2 | COMPLETED | Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas |
| NCT07109518 | PHASE1 | RECRUITING | uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies |
| NCT02512497 | PHASE1 | COMPLETED | Romidepsin Maintenance After Allogeneic Stem Cell Transplantation |
| NCT04480788 | PHASE1 | UNKNOWN | CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study |
| NCT05290155 | PHASE1 | COMPLETED | Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies |
| NCT05620680 | Not specified | RECRUITING | CD7 CAR-T Cells in T-cell Lymphoma/Leukemia |
| NCT02652715 | Not specified | COMPLETED | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| MERCAPTOPURINE ANHYDROUS | 4 | 3 |
| ASPARAGINASE | 4 | 1 |
| CALASPARGASE PEGOL | 4 | 1 |
| DARATUMUMAB | 4 | 1 |
| NELARABINE | 4 | 1 |
| PEGASPARGASE | 4 | 1 |
| ROMIDEPSIN | 4 | 1 |
| THIOGUANINE | 4 | 1 |
| CHEMBL4087968 | 0 | 1 |
| CHEMBL4066465 | 0 | 1 |